Evolution of the Mineralocorticoid Receptor and Gender Difference in Cardiovascular Pathology
Article Sidebar
Main Article Content
Abstract
Retracing the evolution of Mineralocorticoid Receptors (MR) obliges us to take an instructive as well as fascinating leap back in time. This journey teaches us that the relationship between MRs and what we consider their natural ligand, aldosterone, has not always been an exclusive one. MRs operated for a very long time in the oceans and, in any case, in an aquatic environment, stimulated by ligands other than aldosterone, and exercising functions that we still do not know well but which were certainly different from those they currently perform in terrestrial vertebrates, where they maintain normal sodium and body fluids. The history of MRs was initially intertwined with that of female sexual hormones, in particular with progesterone, which was one of the first agonists for MRs, before becoming, with the transition to the terrestrial environment, an important antagonist. This initial intertwining could be the cause of the sexual dimorphism that can be glimpsed when these receptors are overstimulated, as emerges from many experimental studies and some clinical data and/or when antagonistic drugs for these receptors are studied. This must be taken into account in the planning of clinical studies, especially randomized controlled trials, in which the presence of the two sexes must always be well balanced and in the interpretation of the results which must always be performed being well aware of the gender of participants. This does not always happen, however.
Article Details
Copyright (c) 2025 Zuccalà A.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Journal of Cardiology and Cardiovascular Medicine is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | 
Open Access by Journal of Cardiology and Cardiovascular Medicine is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
| Permission to read and download | ✓ |
| Permission to display in a repository | ✓ |
| Permission to translate | ✓ |
| Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
Rossier BC, Baker ME, Studer RA. Epithelial sodium transport and its control by aldosterone: The story of our internal environment revisited. Physiol Rev. 2015;95:297–340. Available from: https://doi.org/10.1152/physrev.00011.2014
Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237:268–275. Available from: https://doi.org/10.1126/science.3037703
Funder JW. Aldosterone and mineralocorticoid receptors—physiology and pathophysiology. Int J Mol Sci. 2017;18:1032–40. Available from: https://doi.org/10.3390/ijms18051032
Baker ME, Katsu Y. 30 years of the mineralocorticoid receptor: Evolution of the mineralocorticoid receptor: sequence, structure and function. J Endocrinol. 2017;234:T1–T6. Available from: https://doi.org/10.1530/joe-16-0661
Bridgham JT, Carroll SM, Thornton JW. Evolution of hormone–receptor complexity by molecular exploitation. Science. 2006;312:97–101. Available from: https://doi.org/10.1126/science.1123348
Close DA, Yun SS, McCormick SD, Wildbill AJ, Li W. 11-deoxycortisol is a corticosteroid hormone in the lamprey. Proc Natl Acad Sci U S A. 2010;107:13942–13947. Available from: https://doi.org/10.1073/pnas.0914026107
Wang H, Bussy U, Chung-Davidson YW, Li W. Ultra-performance liquid chromatography tandem mass spectrometry for simultaneous determination of natural steroid hormones in sea lamprey (Petromyzon marinus) plasma and tissues. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1009–1010:170–178. Available from: https://doi.org/10.1016/j.jchromb.2015.12.030
Sakamoto T, Mori C, Minami S, Takahashi H, Abe T, Ojima D, et al. Corticosteroids stimulate the amphibious behavior in mudskipper: Potential role of mineralocorticoid receptors in teleost fish. Physiol Behav. 2011;104:923–928. Available from: https://doi.org/10.1016/j.physbeh.2011.06.002
Pippal JB, Cheung CM, Yao YZ, Brennan FE, Fuller PJ. Characterization of the zebrafish (Danio rerio) mineralocorticoid receptor. Mol Cell Endocrinol. 2011;332:58–66. Available from: https://doi.org/10.1016/j.mce.2010.09.014
Sugimoto A, Oka K, Sato R, Adachi S, Baker ME, Katsu Y. Corticosteroid and progesterone transactivation of mineralocorticoid receptors from Amur sturgeon and tropical gar. Biochem J. 2016;473:3655–3665. Available from: https://doi.org/10.1042/bcj20160579
Fuller PJ, Yao Y, Jin R, He S, Martín-Fernández B, Young MJ, et al. Molecular evolution of the switch for progesterone and spironolactone from mineralocorticoid receptor agonist to antagonist. Proc Natl Acad Sci U S A. 2019;116:18578–18583. Available from: https://doi.org/10.1073/pnas.1903172116
Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science. 2000;289:119–123. Available from: https://doi.org/10.1126/science.289.5476.119
Zhang J, Simisky J, Tsai FT, Geller DS. A critical role of helix 3-helix 5 interaction in steroid hormone receptor function. Proc Natl Acad Sci U S A. 2005;102:2707–2712. Available from: https://doi.org/10.1073/pnas.0409663102
Hindosh N, Hindosh R, Dada B, Bal S. Geller syndrome: A rare cause of persistent hypokalemia during pregnancy. Cureus. 2022;14:e26272. Available from: https://doi.org/10.7759/cureus.26272
Tian J, Xiang F, Wang L, Wu X, Shao L, Ma L, et al. Liddle syndrome with a SCNN1A mutation: A case report and literature review. Kidney Blood Press Res. 2024;49:831–838. Available from: https://doi.org/10.1159/000540522
Yang KQ, Lu CX, Fan P, Zhang Y, Meng X, Dong XQ, et al. Genetic screening of SCNN1B and SCNN1G genes in early-onset hypertensive patients helps to identify Liddle syndrome. Clin Exp Hypertens. 2018;40:107–111. Available from: https://doi.org/10.1080/10641963.2017.1334799
Pagani L, Diekmann Y, Sazzini M, De Fanti S, Rondinelli M, Farnetti E, et al. Three reportedly unrelated families with Liddle syndrome inherited from a common ancestor. Hypertension. 2018;71:273–279. Available from: https://doi.org/10.1161/hypertensionaha.117.10491
Lu YT, Fan P, Zhang D, Zhang Y, Meng X, Zhang QY, et al. Overview of monogenic forms of hypertension combined with hypokalemia. Front Pediatr. 2021;8:543309. Available from: https://doi.org/10.3389/fped.2020.543309
Lumbers ER, Pringle KG. Roles of the circulating renin-angiotensin-aldosterone system in human pregnancy. Am J Physiol Regul Integr Comp Physiol. 2014;306:R91–R101. Available from: https://doi.org/10.1152/ajpregu.00034.2013
Scaife PJ, Mohaupt MG. Salt, aldosterone and extrarenal Na+ - sensitive responses in pregnancy. Placenta. 2017;56:53–58. Available from: https://doi.org/10.1016/j.placenta.2017.01.100
Baker ME, Katsu Y. Progesterone: An enigmatic ligand for the mineralocorticoid receptor. Biochem Pharmacol. 2020;177:113976. Available from: https://doi.org/10.1016/j.bcp.2020.113976
Boschitsch E, Mayerhofer S, Magometschnigg D. Hypertension in women: the role of progesterone and aldosterone. Climacteric. 2010;13:307–313. Available from: http://dx.doi.org/10.3109/13697131003624649
Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005;308:1583–1587. Available from: https://doi.org/10.1126/science.1112062
Pechère-Bertschi A, Burnier M. Female sex hormones, salt, and blood pressure regulation. Am J Hypertens. 2004;17:994–1001. Available from: https://doi.org/10.1016/j.amjhyper.2004.08.009
Barton M, Meyer MR. Postmenopausal hypertension: mechanisms and therapy. Hypertension. 2009;54:11–18. Available from: https://doi.org/10.1161/HYPERTENSIONAHA.108.120022
Schulman IH, Aranda P, Raij L, Veronesi M, Aranda FJ, Martin R. Surgical menopause increases salt sensitivity of blood pressure. Hypertension. 2006;47:1168–1174. Available from: https://doi.org/10.1161/01.HYP.0000218857.67880.75
Olivieri O, Pizzolo F, Ciacciarelli A, Corrocher R, Signorelli D, Falcone S, et al. Menopause, not aldosterone-to-renin ratio, predicts blood pressure response to a mineralocorticoid receptor antagonist in primary care hypertensive patients. Am J Hypertens. 2008;21:976–982. Available from: https://doi.org/10.1038/ajh.2008.234
Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, et al. Vascular effects of early versus late postmenopausal treatment with estradiol: The ELITE Research Group. N Engl J Med. 2016;374:1221–1231. Available from: https://doi.org/10.1056/nejmoa1505241
Barton M, Meyer MR, Haas E. Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits? Arterioscler Thromb Vasc Biol. 2007;27:1669–1672. Available from: https://doi.org/10.1161/ATVBAHA.106.130260
Eisenhofer G, Peitzsch M, Kaden D, Langton K, Pamporaki C, Masjkur J, et al. Reference intervals for plasma concentrations of adrenal steroids measured by LC-MS/MS: Impact of gender, age, oral contraceptives, body mass index and blood pressure status. Clin Chim Acta. 2017;470:115–124. Available from: https://doi.org/10.1016/j.cca.2017.05.002
Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res. 2002;53:688–708. Available from: https://doi.org/10.1016/S0008-6363(01)00527-2
Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 1995;80:1816–1821. Available from: https://doi.org/10.1210/jcem.80.6.7775629
Pérez-López FR. Clinical experiences with drospirenone: from reproductive to postmenopausal years. Maturitas. 2008;60:78–91. Available from: https://doi.org/10.1016/j.maturitas.2008.03.009
Palacios S, Foidart JM, Genazzani AR. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas. 2006;55:297–307. Available from: https://doi.org/10.1016/j.maturitas.2006.07.009
Đogo A, Dožić B, Vujović S, Srebro D, Dožić I. Effects of continuous combined oral drospirenone-estradiol on blood pressure, body weight, and lipid profile in early menopausal women. Indian J Med Res. 2021;154:857–865. Available from: https://doi.org/10.4103/ijmr.ijmr_478_20
Regitz-Zagrosek V, Oertelt-Prigione S, Prescott E, Franconi F, Gerdts E, Foryst-Ludwig A, et al. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. Eur Heart J. 2016;37:24–34. Available from: https://doi.org/10.1093/eurheartj/ehv598
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–e603. Available from: https://doi.org/10.1161/cir.0000000000000485
Wild RA, Larson JC, Crandall CJ, Shadyab AH, Allison M, Gass M, et al. Hormone therapy formulation, dose, route of delivery, and risk of hypertension: findings from the Women’s Health Initiative Observational Study (WHI-OS). Menopause. 2021;28:1108–1116. Available from: https://doi.org/10.1097/gme.0000000000001828
Zhang GQ, Chen JL, Luo Y, Mathur MB, Anagnostis P, Nurmatov U, et al. Menopausal hormone therapy and women’s health: an umbrella review. PLoS Med. 2021;18:e1003731. Available from: https://doi.org/10.1371/journal.pmed.1003731
Cowley AW Jr. The concept of autoregulation of total blood flow and its role in hypertension. Am J Med. 1980;68:906–916. Available from: https://doi.org/10.1016/0002-9343(80)90225-9
Wenstedt EFE, Oppelaar JJ, Besseling S, Rorije NMG, Olde Engberink RHG, Oosterhof A, et al. Distinct osmoregulatory responses to sodium loading in patients with altered glycosaminoglycan structure: a randomized cross-over trial. J Transl Med. 2021;19:38. Available from: https://link.springer.com/article/10.1186/s12967-021-02700-0
Titze J, Shakibaei M, Schafflhuber M, Schulze-Tanzil G, Porst M, Schwind KH, et al. Glycosaminoglycan polymerization may enable osmotically inactive Na+ storage in the skin. Am J Physiol Heart Circ Physiol. 2004;287:H203–H208. Available from: https://doi.org/10.1152/ajpheart.01237.2003
Kopp C, Linz P, Dahlmann A, Hammon M, Jantsch J, Müller DN, et al. 23Na magnetic resonance imaging-determined tissue sodium in healthy subjects and hypertensive patients. Hypertension. 2013;61:635–640. Available from: https://doi.org/10.1161/hypertensionaha.111.00566
Barbaro NR, Foss JD, Kryshtal DO, Tsyba N, Kumaresan S, Xiao L, et al. Dendritic cell amiloride-sensitive channels mediate sodium-induced inflammation and hypertension. Cell Rep. 2017;21:1009–1020. Available from: https://doi.org/10.1016/j.celrep.2017.10.002
Kirabo A, Fontana V, de Faria AP, Loperena R, Galindo CL, Wu J, et al. DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest. 2014;124:4642–4656. Available from: https://doi.org/10.1172/jci74084
Van Beusecum JP, Barbaro NR, McDowell Z, Aden LA, Xiao L, Pandey AK, et al. High salt activates CD11c+ antigen-presenting cells via SGK1 (serum glucocorticoid kinase 1) to promote renal inflammation and salt-sensitive hypertension. Hypertension. 2019;74:555–563. Available from: https://doi.org/10.1161/hypertensionaha.119.12761
Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, Harrison DG. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010;55:500–507. Available from: https://doi.org/10.1161/HYPERTENSIONAHA.109.145094
Norlander AE, Madhur MS, Harrison DG. The immunology of hypertension. J Exp Med. 2018;215:21–33. Available from: https://doi.org/10.1084/jem.20171773
Ruggeri Barbaro NR, Van Beusecum J, Xiao L, do Carmo L, Pitzer A, Loperena R, et al. Sodium activates human monocytes via the NADPH oxidase and isolevuglandin formation. Cardiovasc Res. 2021;117:1358–1371. Available from: https://doi.org/10.1093/cvr/cvaa207
Wu J, Saleh MA, Kirabo A, Itani HA, Montaniel KR, Xiao L, et al. Immune activation caused by vascular oxidation promotes fibrosis and hypertension. J Clin Invest. 2016;126:50–67. Available from: https://doi.org/10.1172/JCI80761
Sahinoz M, Elijovich F, Ertuglu LA, Ishimwe J, Pitzer A, Saleem M, et al. Salt sensitivity of blood pressure in Blacks and women: a role of inflammation, oxidative stress, and epithelial Na+ channel. Antioxid Redox Signal. 2021;35:1477–1493. Available from: https://doi.org/10.1089/ars.2021.0212
Sun XN, Li C, Liu Y, Du LJ, Zeng MR, Zheng XJ, et al. T-cell mineralocorticoid receptor controls blood pressure by regulating interferon-gamma. Circ Res. 2017;120:1584–1597. Available from: https://doi.org/10.1161/circresaha.116.310480
Veiras LC, Shen JZY, Bernstein EA, Regis GC, Cao D, Okwan-Duodu D, et al. Renal inflammation induces salt sensitivity in male db/db mice through dysregulation of ENaC. J Am Soc Nephrol. 2021;32:1131–1149. Available from: https://doi.org/10.1681/asn.2020081112
Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role of the T cell in the genesis of angiotensin II-induced hypertension and vascular dysfunction. J Exp Med. 2007;204:2449–2460. Available from: https://doi.org/10.1084/jem.20070657
Ji H, Zheng W, Li X, Liu J, Wu X, Zhang MA, et al. Sex-specific T-cell regulation of angiotensin II-dependent hypertension. Hypertension. 2014;64:573–582. Available from: https://doi.org/10.1161/HYPERTENSIONAHA.114.03663
Crislip GR, Sullivan JC. T-cell involvement in sex differences in blood pressure control. Clin Sci (Lond). 2016;130:773–783. Available from: https://doi.org/10.1042/cs20150620
Pollow DP Jr, Uhlorn JA, Sylvester MA, Romero-Aleshire MJ, Uhrlaub JL, Lindsey ML, et al. Menopause and FOXP3+ Treg cell depletion eliminate female protection against T cell-mediated angiotensin II hypertension. Am J Physiol Heart Circ Physiol. 2019;317:H415–H423. Available from: https://doi.org/10.1152/ajpheart.00792.2018
Szekeres-Bartho J, Barakonyi A, Par G, Polgar B, Palkovics T, Szereday L. Progesterone as an immunomodulatory molecule. Int Immunopharmacol. 2001;1:1037–1048. Available from: https://doi.org/10.1016/S1567-5769(01)00035-2
Arck P, Hansen PJ, Mulac Jericevic B, Piccinni MP, Szekeres-Bartho J. Progesterone during pregnancy: endocrine-immune cross talk in mammalian species and the role of stress. Am J Reprod Immunol. 2007;58:268–279. Available from: https://doi.org/10.1111/j.1600-0897.2007.00512.x
Shah NM, Lai PF, Imami N, Johnson MR. Progesterone-related immune modulation of pregnancy and labor. Front Endocrinol (Lausanne). 2019;10:198. Available from: https://doi.org/10.3389/fendo.2019.00198
Buyon JP, Korchak HM, Rutherford LE, Ganguly M, Weissmann G. Female hormones reduce neutrophil responsiveness in vitro. Arthritis Rheum. 1984;27:623–630. Available from: https://doi.org/10.1002/art.1780270604
Ceia F, Fonseca C, Mota T, Morais H, Matias F, de Sousa A, et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail. 2002;4:531–539. Available from: https://doi.org/10.1016/s1388-9842(02)00034-x
Cai A, Qiu W, Xia S, Zhou Y, Chen J, Tan N, et al. Sex-specific characteristics and outcomes in hospitalized heart failure with preserved ejection fraction: the China Cardiovascular Association Database-Heart Failure Center Registry. Eur Heart J. 2023;44:4715–4718. Available from: https://doi.org/10.1093/eurheartj/ehad619
Merrill M, Sweitzer NK, Lindenfeld J, Kao DP. Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: A secondary analysis of TOPCAT trial. JACC Heart Fail. 2019;7:228–238. Available from: https://doi.org/10.1016/j.jchf.2019.01.003
Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR, Anglo-Scandinavian Cardiac Outcomes Trial I. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839–845. Available from: https://doi.org/10.1161/01.hyp.0000259805.18468.8c
Faulkner JL, Harwood D, Bender L, Shrestha L, Brands MW, Morwitzer MJ, Kennard S, Antonova G, Belin de Chantemele EJ. Lack of suppression of aldosterone production leads to salt-sensitive hypertension in female but not male balb/c mice. Hypertension. 2018;72:1397–1406. Available from: https://doi.org/10.1161/hypertensionaha.118.11303
Faulkner JL, Kennard S, Huby AC, Antonova G, Lu Q, Jaffe IZ, et al. Progesterone predisposes females to obesity-associated leptin-mediated endothelial dysfunction via upregulating endothelial mineralocorticoid receptor expression. Hypertension. 2019;74:678–686. Available from: https://doi.org/10.1161/hypertensionaha.119.12802
Clemmer JS, Faulkner JL, Mullen AJ, Butler KR, Hester RL. Sex-specific responses to mineralocorticoid receptor antagonism in hypertensive African American males and females. Biol Sex Differ. 2019;10:24. Available from: https://bsd.biomedcentral.com/articles/10.1186/s13293-019-0238-6
Garg R, Rao AD, Baimas-George M, Hurwitz S, Foster C, Shah RV, Jerosch-Herold M, et al. Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes. Diabetes. 2015;64:236–242. Available from: https://doi.org/10.2337/db14-0670
Haas AV, Rosner BA, Kwong RY, Rao AD, Garg R, Di Carli MF, et al. Sex differences in coronary microvascular function in individuals with type 2 diabetes. Diabetes. 2019;68:631–636. Available from: https://doi.org/10.2337/db18-0650
Wolter NL, Jaffe IZ. Emerging vascular cell-specific roles for mineralocorticoid receptor: implications for understanding sex differences in cardiovascular disease. Am J Physiol Cell Physiol. 2023;324(1):C193–C204. Available from: https://doi.org/10.1152/ajpcell.00372.2022
Woitowich NC, Beery A, Woodruff T. A 10-year follow-up study of sex inclusion in the biological sciences. Elife. 2020;9:e56344. Available from: https://doi.org/10.7554/elife.56344
Daitch V, Turjeman A, Poran I, Tau N, Ayalon-Dangur I, Nashashibi J, et al. Underrepresentation of women in randomized controlled trials: a systematic review and meta-analysis. Trials. 2022;23(1):1038. Available from: https://doi.org/10.1186/s13063-022-07004-2